18 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B Downtrend
Article Searches
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct http://www.zacks.com/stock/news/355654/novo-nordisk-gets-fda-nod-for-haemophilia-drug-esperoct?cid=CS-ZC-FT-355654 Feb 20, 2019 - Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-ZC-FT-356445 Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus http://www.zacks.com/stock/news/357166/ophthotechs-opht-q4-loss-wider-gene-therapy-in-focus?cid=CS-ZC-FT-357166 Feb 27, 2019 - Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
What's in the Cards for Aeterna (AEZS) This Earnings Season? http://www.zacks.com/stock/news/357560/whats-in-the-cards-for-aeterna-aezs-this-earnings-season?cid=CS-ZC-FT-357560 Mar 04, 2019 - Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
Sangamo Rises on Positive Phase I/II Hemophilia Study Data http://www.zacks.com/stock/news/370133/sangamo-rises-on-positive-phase-i-ii-hemophilia-study-data?cid=CS-ZC-FT-370133 Apr 03, 2019 - Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
Can Allergan (AGN) Beat Earnings Estimates Again in Q1? http://www.zacks.com/stock/news/406700/can-allergan-agn-beat-earnings-estimates-again-in-q1?cid=CS-ZC-FT-406700 May 01, 2019 - Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales
Novo Nordisk A/S (NVO) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/05/03/novo-nordisk-as-nvo-q1-2019-earnings-call-transcri.aspx?source=iedfolrf0000001 May 03, 2019 - NVO earnings call for the period ending March 31, 2019.
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jørgensen on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4259913-novo-nordisk-s-nvo-ceo-lars-fruergaard-jorgensen-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare May 03, 2019 - Novo Nordisk A/S (NYSE:NVO) Q1 2019 Results Conference Call May 03, 2019 07:00 AM ET Company Participants Lars Fruergaard Jørgensen - CEO Karsten Munk Knudsen - CFO Mads Krogsgaard Thomsen - Chief Sci

Pages: 12

<Page 2